Crossmark

Applying Metabolomics and Aptamer-Based Proteomics to Determine Pathophysiologic Differences in Decompensated Cirrhosis Patients Hospitalized with Acute Kidney Injury

Crossref DOI link: https://doi.org/10.1007/s10620-025-09223-4

Published Online: 2025-08-01

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cullaro, Giuseppe

Allegretti, Andrew S.

Patidar, Kavish R.

Verna, Elizabeth C.

Lai, Jennifer C.
Funding

Funding for this research was provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK026743)

National Institute of Diabetes and Digestive and Kidney Diseases (K23DK128567)

American Association for the Study of Liver Diseases (CTORA)

National Institute on Aging (R01AG059183)
License Information

Text and Data Mining valid from 2025-08-01

Version of Record valid from 2025-08-01
More Information

Article History

Received: 29 April 2024

Accepted: 28 June 2025

First Online: 1 August 2025

Declarations

:

: The authors of this manuscript have conflicts of interest to disclose: Giuseppe Cullaro—Research Support: Mallinckrodt Pharmaceuticals; Consultant: Ocelot Bio; Retro Biosciences; Jennifer C. Lai—Consultant: GenFit Corp; Advisory Board: Novo Nordisk; Research support: Gore Therapeutics; Site investigator: Lipocine; Andrew S. Allegretti—Consultant: Mallinckrodt Pharmaceuticals and Ocelot Bio; All others have nothing to disclose.

Document is current

Any future updates will be listed below